German-based biotech firm Mologen has reported positive first combination data of its TLR9 agonist lefitolimod with checkpoint inhibitors in preclinical tumour models.

Lefitolimod is a TLR9 agonist designed to trigger immune system by reactivating its monitoring function.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is being developed for the treatment of first-line maintenance treatment of colorectal cancer and small-cell lung cancer and has been recognised as Immune Surveillance Reactivator (ISR) due to its mechanism of action.

The combination data indicated that in murine tumour models, lefitolimod could increase the anti-tumour effect of checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 antibodies.

The in-vitro experiments conducted further confirmed the positive effect of the combination of lefitolimod with anti-PD-1, when compared to each monotherapeutic approach.

See Also:

"The new results are an important proof-of-concept for the combination approach of lefitolimod with checkpoint inhibitors."

Mologen chief executive officer Mariola Söhngen said: “We believe that patients can benefit from the combination of these immunotherapies due to their modes of action complementing each other.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The new results are an important proof-of-concept for the combination approach of lefitolimod with checkpoint inhibitors.

"Consequently, the data opens further application possibilities for our lead product and supports our ongoing phase I combination study of lefitolimod with the checkpoint inhibitor Yervoy. ”

The clinical trial to evaluate the combination therapy will be conducted in approximately 50-60 patients by MD Anderson Cancer Center, Texas, US, for which Mologen will offer funding and the ISR lefitolimod.

The trail will intially evaluate the best tolerable dose and safety of lefitolimod in combination with Yervoy, with plans for an expansion phase to assess the efficacy of the combination.

Patient enrolment commenced last July and is expected to be completed by the beginning of 2018.